RxDoctor Payments Data

Alakh Gulati

Gastroenterology · Orange City, FLNPI 1407397656

Payments from drug & device makers

$2,093in general payments, 2019–2025

Across 72 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$731
  • AbbVie$485
  • Takeda Pharmaceuticals U.S.A., Inc.$174
  • Olympus America Inc.$141
  • Capsovision, Inc.$105
  • Aimmune Therapeutics, Inc.$98
  • plus $358 from 11 others

What the payments were for

  • Food & beverage$2,093100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,093 in reported general payments places this provider in the 35th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$180,069
Medicare patients
454
Services billed
1,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide33$20,921
VoqueznaVonoprazan Fumarate20$15,332
Colestipol Hcl43$3,657
ClenpiqSod Picosulf/Mag Ox/Citric Ac18$3,108
Omeprazole117$2,457
Sucralfate79$1,619
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl90$1,582
Pantoprazole Sodium105$1,454
Ursodiol13$1,238
Dicyclomine Hcl47$1,019
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$767
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl31$565
Lactulose31$368
LoperamideLoperamide Hcl12$341
Famotidine17$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$485$20,92133 claims
Phathom Pharmaceuticals, Inc.Voquezna$731$15,33220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →